AACR 2020-话题@MedSci - williamhill asia

#AACR 2020#

32篇内容 | 1565人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1853114, encodeId=a78a1853114db, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, objectType=article, longId=193104, objectId=5d7319310411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d7319310411, replyNumber=0, likeNumber=56, createdTime=2020-07-24, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d7319310411, moduleTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5d7319310411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853123, encodeId=cc7f1853123ce, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%, objectType=article, longId=193168, objectId=64ac1931686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ac1931686b, replyNumber=0, likeNumber=50, createdTime=2020-09-25, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ac1931686b, moduleTitle=AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=64ac1931686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853115, encodeId=721f1853115a6, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, objectType=article, longId=193107, objectId=ee7719310e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7719310e83, replyNumber=0, likeNumber=52, createdTime=2021-01-02, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7719310e83, moduleTitle=AACR 2020：大样本NSCLC中的FGFR基因突变结果发布, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ee7719310e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853141, encodeId=eb99185314155, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, objectType=article, longId=196313, objectId=dbde196313ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbde196313ba, replyNumber=0, likeNumber=63, createdTime=2021-01-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbde196313ba, moduleTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dbde196313ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853140, encodeId=28661853140a1, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, objectType=article, longId=193387, objectId=c66b19338e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66b19338e62, replyNumber=0, likeNumber=61, createdTime=2021-02-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66b19338e62, moduleTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c66b19338e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853143, encodeId=7e46185314370, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, objectType=article, longId=196499, objectId=fcb619649997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb619649997, replyNumber=0, likeNumber=52, createdTime=2021-04-04, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb619649997, moduleTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fcb619649997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853119, encodeId=125e185311989, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效, objectType=article, longId=193158, objectId=b7d619315856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7d619315856, replyNumber=0, likeNumber=49, createdTime=2020-12-15, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7d619315856, moduleTitle=AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b7d619315856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853128, encodeId=acb91853128e5, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：基因治疗肾细胞癌获突破，DCR可达75%！, objectType=article, longId=193177, objectId=1d271931e730, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d271931e730, replyNumber=0, likeNumber=102, createdTime=2021-04-14, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d271931e730, moduleTitle=AACR 2020：基因治疗肾细胞癌获突破，DCR可达75%！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1d271931e730)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853130, encodeId=d8fd1853130f6, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, objectType=article, longId=193179, objectId=833e1931e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833e1931e9c2, replyNumber=0, likeNumber=56, createdTime=2020-08-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833e1931e9c2, moduleTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=833e1931e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853117, encodeId=a26e185311e80, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, objectType=article, longId=193109, objectId=bc64193109cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc64193109cc, replyNumber=0, likeNumber=65, createdTime=2020-08-07, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc64193109cc, moduleTitle=AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bc64193109cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853142, encodeId=f77d185314290, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, objectType=article, longId=196482, objectId=3e9419648230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9419648230, replyNumber=0, likeNumber=54, createdTime=2020-12-17, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9419648230, moduleTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3e9419648230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853116, encodeId=05dd18531161c, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, objectType=article, longId=193108, objectId=28561931082d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28561931082d, replyNumber=0, likeNumber=52, createdTime=2020-07-23, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28561931082d, moduleTitle=AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=28561931082d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853145, encodeId=da7d185314581, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, objectType=article, longId=196693, objectId=dce7196693fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce7196693fd, replyNumber=0, likeNumber=62, createdTime=2021-04-23, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce7196693fd, moduleTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dce7196693fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853126, encodeId=e23e185312623, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, objectType=article, longId=193174, objectId=9c411931e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c411931e4ea, replyNumber=0, likeNumber=58, createdTime=2020-11-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c411931e4ea, moduleTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9c411931e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853137, encodeId=317e185313eee, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=54, createdTime=2021-02-15, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853118, encodeId=839d185311806, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析, objectType=article, longId=193155, objectId=a1ad1931551a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1ad1931551a, replyNumber=0, likeNumber=61, createdTime=2020-08-04, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1ad1931551a, moduleTitle=AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a1ad1931551a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853120, encodeId=bccb185312050, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究, objectType=article, longId=193160, objectId=a05f193160ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05f193160ff, replyNumber=0, likeNumber=49, createdTime=2021-04-04, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05f193160ff, moduleTitle=AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a05f193160ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853132, encodeId=9c381853132a7, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, objectType=article, longId=193181, objectId=fa86193181f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa86193181f6, replyNumber=0, likeNumber=50, createdTime=2020-12-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa86193181f6, moduleTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fa86193181f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853144, encodeId=313a185314416, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, objectType=article, longId=196545, objectId=5a8619654517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8619654517, replyNumber=0, likeNumber=52, createdTime=2021-04-20, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8619654517, moduleTitle=AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5a8619654517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853134, encodeId=5a4d18531349e, content=<a href='/topic/show?id=f1b41665ac' target=_blank style='color:#2F92EE;'>#AACR 2020#</a>, objectTitle=AACR 2020：MET新药Bozitinib用于NSCLC，疾病控制率90%, objectType=article, longId=193183, objectId=1bf61931836e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf61931836e, replyNumber=0, likeNumber=60, createdTime=2020-07-16, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf61931836e, moduleTitle=AACR 2020：MET新药Bozitinib用于NSCLC，疾病控制率90%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1bf61931836e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

AACR 2020

2020-05-29

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究

2020-07-24

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：伯瑞替尼治疗MET异常NSCLC，ORR达30.5%

2020-09-25

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：大样本NSCLC中的FGFR基因突变结果发布

2021-01-02

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据

2021-01-30

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果

2021-02-18

zhouqu_8 (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用

2021-04-04

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效

2020-12-15

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：基因治疗肾细胞癌获突破，DCR可达75%！

2021-04-14

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现

2020-08-30

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：STK11和KEAP1突变影响K药一线治疗PDL1阳性患者（Keynote 042研究）

2020-08-07

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗

2020-12-17

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：豪森药业阿美替尼用于EGFR突变耐药的NSCLC患者结果公布

2020-07-23

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率

2021-04-23

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月

2020-11-13

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2021-02-15

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析

2020-08-04

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：波奇替尼治疗NSCLC的EGFR 20ins的II期研究

2021-04-04

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%

2020-12-18

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：PD-L1单抗Tecentriq联合卡铂和依托泊苷，可提高小细胞肺癌SCLC生存率

2021-04-20

tamgche (审核中...)

前往app查看评论内容

#AACR 2020#

AACR 2020：MET新药Bozitinib用于NSCLC，疾病控制率90%

2020-07-16

科室
- - 订阅+
  - 更多科室
工具
服务